8-K - CervoMed Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

CervoMed Inc. announced completion of a Phase 1 healthy volunteer study evaluating pharmacokinetics of a new stable crystal form of neflamapimod and selected a 50mg TID dosing regimen for its planned Phase 3 trial in dementia with Lewy bodies (DLB), targeting plasma concentrations matching the clinically active DP Batch B from the Phase 2b RewinD-LB trial extension.

Key Takeaways

1Completed Phase 1 PK study with stable crystal form of neflamapimod using new controlled manufacturing process

2Selected 50mg TID dosing for planned Phase 3 DLB trial to achieve plasma concentrations of DP Batch B

3PK profile of 40mg stable crystal form largely overlaps with 40mg DP Batch B from Phase 2b extension

4Plans to initiate global Phase 3 DLB trial in second half of 2026, subject to funding

5New process addresses prior polymorph conversion and bioavailability issues with DP Batch A

Current Report Details

Event Type

Regulation Fd

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

of this Current Report on Form 8-K. -- The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Se

Regulation Fd

8.01

Other Events The information set forth in the first two paragraphs of the Company’s March 4, 2026, press release is incorporated by reference into this Item 8.0

Other Event

9.01

Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, issued March 4, 2026 104 Cover Page Interactive Data File (embedded w

Exhibits Only

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1